Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tirelizumab in Combination With Chemoradiation in Patients With Unresectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma：A Single Arm Phase II Clinical Study

NCT05528367 is registered in ClinicalTrials.gov with Zhejiang Cancer Hospital as lead sponsor.

NCT NCT05528367
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05528367 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tirelizumab in Combination With Chemoradiation in Patients With Unresectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma：A Single Arm Phase II Clinical Study
Lead sponsor
Zhejiang Cancer Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
January 1, 2022
Completion date
December 31, 2024
Enrollment
33 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced gastric cancer